Actelion (United States)

Recent papers from Actelion (United States)

1. Long‐Term Outcomes in Patients With Connective Tissue Disease–Associated Pulmonary Arterial Hypertension in the Modern Treatment Era: Meta‐Analyses of Randomized, Controlled Trials and Observational RegistriesArthritis & Rheumatology · 2021
2. Risk assessment in patients with functional class II pulmonary arterial hypertension: Comparison of physician gestalt with ESC/ERS and the REVEAL 2.0 risk scorePLoS ONE · 2020
3. Pulmonary Arterial Hypertension—Symptoms and Impact Questionnaire: feasibility of utilizing one‐day versus seven‐day symptom reportingPulmonary Circulation · 2020
4. Medication adherence, hospitalization, and healthcare resource utilization and costs in patients with pulmonary arterial hypertension treated with endothelin receptor antagonists or phosphodiesterase type‐5 inhibitorsPulmonary Circulation · 2019
5. Approaching Higher Dimension Imaging Data Using Cluster-Based Hierarchical Modeling in Patients with Heart Failure Preserved Ejection FractionScientific Reports · 2019
6. Predicting Survival in Patients With Pulmonary Arterial HypertensionCHEST Journal · 2019
7. Treatment patterns, healthcare resource utilization, and healthcare costs among patients with pulmonary arterial hypertension in a real‐world US databasePulmonary Circulation · 2018
8. Measurement of Quality of Life in Patients with Mycosis Fungoides/Sézary Syndrome Cutaneous T-Cell Lymphoma: Development of an Electronic InstrumentJournal of Medical Internet Research · 2018
9. Healthcare resource utilization, costs of care, and treatment of mycosis fungoides cutaneous T-cell lymphoma patterns in a large managed care population: a retrospective US claims-based analysisJournal of Dermatological Treatment · 2018
10. Psychometric Validation of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT) QuestionnaireCHEST Journal · 2018
11. Bosentan‐based, treat‐to‐target therapy in patients with pulmonary arterial hypertension: results from the COMPASS‐3 studyPulmonary Circulation · 2017
12. Healthcare resource utilization and costs for patients with pulmonary arterial hypertension: real-world documentation of functional classJournal of Medical Economics · 2017
13. Assessing risk in pulmonary arterial hypertension: what we know, what we don'tEuropean Respiratory Journal · 2017
14. P5462Evaluation of macitentan in patients with Eisenmenger syndrome: results from the randomised controlled MAESTRO studyEuropean Heart Journal · 2017
15. Effect of Warfarin Treatment on Survival of Patients With Pulmonary Arterial Hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL)Circulation · 2015
16. Development of macitentan for the treatment of pulmonary arterial hypertensionAnnals of the New York Academy of Sciences · 2015
17. A double-blind, randomized, placebo-controlled trial studying the effects of Saccharomyces boulardii on the gastrointestinal tolerability, safety, and pharmacokinetics of miglustatOrphanet Journal of Rare Diseases · 2015
18. Five-Year Outcomes of Patients Enrolled in the REVEAL RegistryCHEST Journal · 2015
19. AMP promotes oxygen consumption and ATP synthesis in heart mitochondria through the adenylate kinase reaction: an NMR spectroscopy and polarography studyCell Biochemistry and Function · 2015
20. Hospitalization and Survival in Patients Using Epoprostenol for Injection in the PROSPECT Observational StudyCHEST Journal · 2014